SpaceX is finally going public and it might be the most hyped IPO in a generation. But does that make it a buy, a trade, or a trap? Luke and Krzysztof have completely different plans, and neither one is obvious. This week also covers a tiny autonomous aviation startup that

The AI infrastructure land grab is accelerating — and this week, Krzysztof drops a deep dive into his #1 portfolio holding that rewrites the bull case entirely. Meanwhile, Luke’s longtime fintech darling just got hit with a half-billion-euro money laundering investigation on the same week it relisted on NASDAQ. Timing

Four investors. Four wildly different portfolios. One crossover episode that gets uncomfortably honest about conviction, concentration, and whether the rules of investing have actually changed. Wall Street Wildlife’s Luke and Krzysztof team up with Bear and Drowsy from Shooting the Bull Pod — and the result is one of the

Three stocks, three debates, one ticking clock. This week on Wall Street Wildlife, Krzysztof drops a live biotech catalyst with a 24-hour window, Luke defends his 20-year ‘sugar daddy’ holding, and a Latin American e-commerce giant is quietly being stress-tested. Plus: Krzysztof reveals a wild AI experiment he’s launching in

Four companies. Two hosts. One brutal question: which stocks deserve your conviction right now, and which ones are just good stories hiding ugly fundamentals? This week, Luke and Krzysztof go bull-vs-bear on four names — and the conclusions might surprise you. The “too hard pile” is getting bigger, and maybe

The largest UK fintech is abandoning the London Stock Exchange for the NASDAQ — and Luke thinks it could be an inflection point. This solo deep-dive makes the bull AND bear case on one of his highest-conviction holdings, right before the dual listing goes live. Here’s what every investor needs

Luke sold two stocks this week. Not because earnings disappointed or guidance missed — but because he ran the numbers on what AI actually does to software valuations, and the math got uncomfortable fast. Meanwhile, Krzysztof turned a 70% options loss into a breakeven exit… then watched the stock moon

200 million eczema sufferers. A leading drug that fails more than half of them. A cancer-causing alternative that still projects $5 billion in sales. And a tiny 60-person San Francisco biotech that may have cracked the code — with a Nobel Prize-validated mechanism the market is somehow pricing at near-zero.

The AI arms race is here, and it’s shaking up the cybersecurity landscape. Is it time to panic, or is this a buying opportunity? We dive deep into the AI doomsday fears and how it could impact our portfolios. Plus:🧠 Axon’s stock-based comp problem: a great company, TERRIBLE stock? $AXON📊

🎰 What happens when two investors hit Vegas with their Patreons? Craps strategies, poker tournaments, and a $50 bounty on Monkey’s scalp🧠 The one investing mistake almost everyone makes — and why borrowed conviction will cost you everything when the market turns🃏 Why poker pros keep becoming legendary investors —